- Home
- ANIX vs SKYE Comparison
ANIX vs SKYE Comparison
Compare ANIX & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANIX
- SKYE
- Stock Information
- Founded
- ANIX 1982
- SKYE 2012
- Country
- ANIX United States
- SKYE United States
- Employees
- ANIX N/A
- SKYE N/A
- Industry
- ANIX Biotechnology: Pharmaceutical Preparations
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- ANIX Health Care
- SKYE Health Care
- Exchange
- ANIX Nasdaq
- SKYE Nasdaq
- Market Cap
- ANIX 108.9M
- SKYE 115.9M
- IPO Year
- ANIX 1987
- SKYE N/A
- Fundamental
- Price
- ANIX $3.01
- SKYE $3.41
- Analyst Decision
- ANIX Strong Buy
- SKYE Buy
- Analyst Count
- ANIX 3
- SKYE 6
- Target Price
- ANIX $9.00
- SKYE $16.60
- AVG Volume (30 Days)
- ANIX 110.3K
- SKYE 467.4K
- Earning Date
- ANIX 09-05-2025
- SKYE 08-07-2025
- Dividend Yield
- ANIX N/A
- SKYE N/A
- EPS Growth
- ANIX N/A
- SKYE N/A
- EPS
- ANIX N/A
- SKYE N/A
- Revenue
- ANIX N/A
- SKYE N/A
- Revenue This Year
- ANIX N/A
- SKYE N/A
- Revenue Next Year
- ANIX N/A
- SKYE N/A
- P/E Ratio
- ANIX N/A
- SKYE N/A
- Revenue Growth
- ANIX N/A
- SKYE N/A
- 52 Week Low
- ANIX $2.07
- SKYE $1.14
- 52 Week High
- ANIX $4.20
- SKYE $7.47
- Technical
- Relative Strength Index (RSI)
- ANIX 40.04
- SKYE 44.99
- Support Level
- ANIX $3.10
- SKYE $3.45
- Resistance Level
- ANIX $3.24
- SKYE $3.84
- Average True Range (ATR)
- ANIX 0.16
- SKYE 0.35
- MACD
- ANIX -0.04
- SKYE -0.12
- Stochastic Oscillator
- ANIX 0.00
- SKYE 13.91
About ANIX Anixa Biosciences Inc.
Anixa Biosciences Inc a cancer-focused biotechnology company, develops vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.